Neuroblastoma

Seminars in Pediatric Surgery

Volumn 21, Issue 1, 2012, Pages 2-14

  Davidoff, Andrew M ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Immunotherapy; Neuroblastic tumors; Neuroblastoma; Risk factors; Targeted therapy

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DNA; DOXORUBICIN; ETOPOSIDE; ISOTRETINOIN; MICRORNA; RETINOID; RETINOL;

ANGIOGENESIS; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CHROMOSOME 11Q; CHROMOSOME 17; CHROMOSOME 1P; COPY NUMBER VARIATION; DNA METHYLATION; EVENT FREE SURVIVAL; GENE MUTATION; HISTOPATHOLOGY; HUMAN; IMMUNOTHERAPY; MOLECULARLY TARGETED THERAPY; NEUROBLASTOMA; OVERALL SURVIVAL; PLOIDY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; X CHROMOSOME;

CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; INFANT; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEUROBLASTOMA; RISK;

EID: 84855873031     PISSN: 10558586     EISSN: 15329453     Source Type: Journal    
DOI: 10.1053/j.sempedsurg.2011.10.009     Document Type: Article

References (104)

1. Brodeur G.M., Castleberry R.P. Neuroblastoma. Principles and Practice of Pediatric Oncology 1993, 739-767. J. B. Lippincott, Philadelphia. 2nd edn. P.A. Pizzo, D.G. Poplack (Eds.).
2. Young J.L., Ries L.G., Silverberg E., et al. Cancer incidence, survival, and mortality for children younger than age 15 years. Cancer 1986, 58:598-602.
3. Brodeur G.M., Nakagawara A. Molecular basis of clinical heterogeneity in neuroblastoma. Am J Pediatr Hematol/Oncol 1992, 14:111-116.
4. Breslow N., McCann B. Statistical estimation of prognosis for children with neuroblastoma. Cancer Res 1971, 31:2098-2103.
5. Evans A.E., D'Angio G.J., Propert K., et al. Prognostic factor in neuroblastoma. Cancer 1987, 59:1853-1859.
6. Brodeur G.M., Seeger R.C., Schwab M., et al. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984, 224:1121-1124.
7. Seeger R.C., Brodeur G.M., Sather H., et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985, 313:1111-1116.
8. Shimada H., Umehara S., Monobe Y., et al. International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: A report from the children's Cancer Group. Cancer 2001, 92:2451-2461.
9. Look A.T., Hayes F.A., Shuster J.J., et al. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: A Pediatric Oncology Group study. J Clin Oncol 1991, 9:581-591.
10. Look A.T., Hayes F.A., Nitschke R., et al. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med 1984, 311:231-235.
11. Brodeur G.M., Pritchard J., Berthold F., et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993, 11:1466-1477.
12. Monclair T., Brodeur G.M., Ambros P.F., et al. The International Neuroblastoma Risk Group (INRG) staging system: An INRG Task Force report. J Clin Oncol 2009, 27:298-303.
13. Cecchetto G., Mosseri V., De Bernardi B., et al. Surgical risk factors in primary surgery for localized neuroblastoma: The LNESG1 study of the European International Society of Pediatric Oncology Neuroblastoma Group. J Clin Oncol 2005, 23:8483-8489.
14. Moroz V., Machin D., Faldum A., et al. Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: A report from the International Neuroblastoma Risk Group Project. Eur J Cancer 2011, 47:561-571.
15. Shimada H., Chatten J., Newton W.A., et al. Histopathologic prognostic factors in neuroblastic tumors: Definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 1984, 73:405-416.
16. Shimada H., Ambros I.M., Dehner L.P., et al. Terminology and morphologic criteria of neuroblastic tumors: Recommendations by the International Neuroblastoma Pathology Committee. Cancer 1999, 86:349-363.
17. Peuchmaur M., d'Amore E.S., Joshi V.V., et al. Revision of the International Neuroblastoma Pathology Classification: Confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular. Cancer 2003, 98:2274-2281.
18. Chatten J., Shimada H., Sather H.N., et al. Prognostic value of histopathology in advanced neuroblastoma: A report from the Children's Cancer Study Group. Hum Pathol 1988, 19:1187-1198.
19. De Bernardi B., Gambini C., Haupt R., et al. Retrospective study of childhood ganglioneuroma. J Clin Oncol 2008, 26:1710-1716.
20. Schwab M., Alitalo K., Klempnauer K.H., et al. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 1983, 305:245-248.
21. Kaneko Y., Kanda N., Maseki N., et al. Different karyotypic patterns in early and advanced stage neuroblastomas. Cancer Res 1987, 47:311-318.
22. Bowman L.C., Castleberry R.P., Cantor A., et al. Genetic staging of unresectable or metastatic neuroblastoma in infants: A Pediatric Oncology Group study. J Natl Cancer Inst 1997, 89:373-380.
23. Brodeur G.M., Sekhon G., Goldstein M.N. Chromosomal aberrations in human neuroblastomas. Cancer 1977, 40:2256-2263.
24. Fong C.T., Dracopoli N.C., White P.S., et al. Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas: Correlation with N-myc amplification. Proc Natl Acad Sci U S A 1989, 86:3753-3757.
25. Gilbert F., Feder M., Balaban G., et al. Human neuroblastomas and abnormalities of chromosomes 1 and 17. Cancer Res 1984, 44:5444-5449.
26. Attiyeh E.F., London W.B., Mossé Y.P., et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 2005, 353:2243-2253.
27. Fujita T., Igarashi J., Okawa E.R., et al. CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas. J Natl Cancer Inst 2008, 100:940-949.
28. Takayama H., Suzuki T., Mugishima H., et al. Deletion mapping of chromosomes 14q and 1p in human neuroblastoma. Oncogene 1992, 7:1185-1189.
29. Baker D.L., Schmidt M.L., Cohn S.L., et al. Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med 2010, 363:1313-1323.
30. Matthay K.K., Villablanca J.G., Seeger R.C., et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999, 341:1165-1173.
31. Rill D.R., Santana V.M., Roberts W.M., et al. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 1994, 84:380-383.
32. Garaventa A., Ladenstein R., Chauvin F., et al. High-dose chemotherapy with autologous bone marrow rescue in advanced stage IV neuroblastoma. Eur J Cancer 1993, 29A:487-491.
33. La Quaglia M.P., Kushner B.H., Su W., et al. The impact of gross total resection on local control and survival in high-risk neuroblastoma. J Pediatr Surg 2004, 39:412-417.
34. Moon S.B., Park K.W., Jung S.E., et al. Neuroblastoma: Treatment outcome after incomplete resection of primary tumors. Pediatr Surg Int 2009, 25:789-793.
35. Castel V., Tovar J.A., Costa E., et al. The role of surgery in stage IV neuroblastoma. J Pediatr Surg 2002, 37:1574-1578.
36. Kiely E.M. The surgical challenge of neuroblastoma. J Pediatr Surg 1994, 29:128-133.
37. Azizkhan R.G., Haase G.M. Current biologic and therapeutic implications in the surgery of neuroblastoma. Semin Surg Oncol 1993, 9:493-501.
38. Medary I., Aronson D., Cheung N.K., et al. Kinetics of primary tumor regression with chemotherapy: Implications for the timing of surgery. Ann Surg Oncol 1996, 3:521-525.
39. Davidoff A.M., Corey B.L., Hoffer F.A., et al. Radiographic assessment of resectability of locoregional disease in children with high-risk neuroblastoma during neoadjuvant chemotherapy. Rediatr Blood Cancer 2005, 44:158-162.
40. Cohn S.L., Pearson A.D., London W.B., et al. The International Neuroblastoma Risk Group (INRG) classification system: An INRG Task Force report. J Clin Oncol 2009, 27:289-297.
41. Cheung N.K. Immunotherapy. Neuroblastoma as a model. Pediatr Clin North Am 1991, 38:425-441.
42. Cheung N.K., Burch L., Kushner B.H., et al. Monoclonal antibody 3F8 can effect durable remissions in neuroblastoma patients refractory to chemotherapy; a phase II trial. Advances in Neuroblastoma Research, vol 3 1991, 395. Wiley-Liss, New York. A.E. Evans, G.J. D'Angio, A.G. Kundson (Eds.).
43. Ozkaynak M.F., Sondel P.M., Krailo M.D., et al. Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (Ch 14.18 with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study. J Clin Oncol 2000, 18:4077-4085.
44. Hank J.A., Surfus J., Gan J., et al. Treatment of neuroblastoma patients with antiganglioside GD2 antibody plus interleukin-2 induces antibody-dependent cellular cytotoxicity against neuroblastoma detected in vitro. J Immunother 1994, 15:29-37.
45. Yu A.L., Gilman A.L., Ozkaynak M.F., et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010, 363:1324-1334.
46. Gelfand M.J. Meta-iodobenzylguanidine in children. Semin Nucl Med 1993, 23:231-242.
47. Lashford L.S., Lewis I.J., Fielding S.L., et al. Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: A United Kingdom children's Cancer Study Group investigation. J Clin Oncol 1992, 10:1889-1896.
48. Haase G.M., Meagher D.P., McNeely L.K., et al. Electron beam intraoperative radiation therapy for pediatric neoplasms. Cancer 1994, 74:740-747.
49. Hoefnagel C.A., Smets L., VoÛte P.A., de Kraku J. Iodine-125-MIBG therapy for neuroblastoma. J Nucl Med 1991, 32:361-362.
50. Polishchuk A.L., DuBois S.G., Haas-Kogan D.A., et al. Response, survival, and toxicity after iodine-131-metaiodobenzylguanidine therapy for neuroblastoma in preadolescents, adolescents, and adults. Cancer 2011, 117:4286-4293.
51. Reynolds C.P., Kane D.J., Einhorn P.A., et al. Response of neuroblastoma to retinoic acid in vitro and in vivo. Prog Clin Biol Res 1991, 366:203-211.
52. Reynolds C.P., Schindler P., Jones D., et al. Comparisons of 13-cisretinoic acid to trans-retronic acid using human neuroblastoma cell lines. Advances in Neuroblastoma Research, vol 4 1994, 237-244. Wiley, New York. A.E. Evans, J.L. Biedler, G. Brodeur (Eds.).
53. Sidell N., Altman A., Haussler M.R., Seeger R.C. Effects of retinoic acid (RA) on the growth and phenotypic expression of several human neuroblastoma cell lines. Exp Cell Res 1983, 148:21-30.
54. Thiele C.J., Reynolds C.P., Israel M.A. Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature 1985, 313:404-406.
55. Di Vinci A., Geido E., Infusini E., Giaretti W. Neuroblastoma cell apoptosis induced by the synthetic retinoid N-(4-hydroxyphenyl)retinamide. Int J Cancer 1994, 59:422-426.
56. Villablanca J.G., Krailo M.D., Ames M.M., et al. Phase I Trial of Oral Fenretinide in Children With High-Risk Solid Tumors: A Report From the Children's Oncolgy Group (CCG:09709). J Clin Oncol 2006, 24:3423-3430.
57. Nagabuchi E., VanderKolk W.E., Une Y., et al. TNP-470 antiangiogenic therapy for advanced murine neuroblastoma. J Pediatr Surg 1997, 32:287-293.
58. Wassberg E., Påhlman S., Westlin J.E., et al. The angiogenesis inhibitor TNP-470 reduces the growth rate of human neuroblastoma in nude rats. Pediatr Res 1997, 41:327-333.
59. Shusterman S., Grupp S.A., Barr R., et al. The angiogenesis inhibitor TNP-470 Effectively Inhibits Human Neuroblastoma xenograft Growth, Especially in the Setting of Subclinical Disease. Clin Cancer Res 2001, 7:977-984.
60. Kim E.S., Serur A., Huang J., et al. Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci U S A 2002, 99:11399-11404.
61. Davidoff A.M., Leary M.A., Ng C.Y., et al. Gene therapy-mediated expression by tumor cells of the angiogenesis inhibitor flk-1 results in inhibition of neuroblastoma growth in vivo. J Pediatr Surg 2001, 36:30-36.
62. Davidoff A.M., Leary M.A., Ng C.Y., et al. Retroviral vector-producer cell mediated angiogenesis inhibition restricts neuroblastoma growth in vivo. Med Pediatr Oncol 2000, 35:638-640.
63. Crawford S.E., Stellmach V., Ranalli M., et al. Pigment epithelium-derived factor (PEDF) in neuroblastoma: A multifunctional mediator of Schwann cell antitumor activity. J Cell Sci 2001, 114:4421-4428.
64. Browder T., Butterfield C.E., Kräling B.M., et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000, 60:1878-1886.
65. Mossé Y.P., Laudenslager M., Longo L., et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008, 455:930-935.
66. Mossé Y.P., Wood A., Maris J.M. Inhibition of ALK signaling for cancer therapy. Clin Cancer Res 2009, 15:5609-5614.
67. Hirota T., Kunitoku N., Sasayama T., et al. Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. Cell 2003, 114:585-598.
68. Shang X., Burlingame S.M., Okcu M.F., et al. Aurora A is a negative prognostic factor and a new therapeutic target in human neuroblastoma. Mol Cancer Ther 2009, 8:2461-2469.
69. Maris J.M., Morton C.L., Gorlick R., et al. Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer 2010, 55:26-34.
70. Barbacid M. Neurotrophic factors and their receptors. Curr Opin Cell Biol 1995, 7:148-155.
71. Levi-Montalcini R. The nerve growth factor 35 years later. Science 1987, 237:1154-1162.
72. Nakagawara A., Arima-Nakagawara M., Scavarda N.J., et al. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 1993, 328:847-854.
73. Nakagawara A., Arima M., Azar C.G., et al. Inverse relationship between trk expression and N-myc amplification in human neuroblastomas. Cancer Res 1992, 52:1364-1368.
74. Nakagawara A., Azar C.G., Scavarda N.J., et al. Expression and function of TRK-B and BDNF in human neuroblastomas. Mol Cell Biol 1994, 14:759-767.
75. Svensson T., Rydén M., Schilling F.H., et al. Coexpression of mRNA for the full-length neurotrophin receptor trk-C and trk-A in favourable neuroblastoma. Eur J Cancer 1997, 33:2058-2063.
76. Evans A.E., Kisselbach K.D., Yamashiro D.J., et al. Antitumor activity of CEP-751 (KT-6587) on human neuroblastoma and medulloblastoma xenografts. Clin Cancer Res 1999, 5:3594-3602.
77. Acheson A., Conover J.C., Fandl J.P., et al. A BDNF autocrine loop in adult sensory neurons prevents cell death. Nature 1995, 374:450-453.
78. Matsumoto K., Wada R.K., Yamashiro J.M., et al. Expression of brain-derived neurotrophic factor and p145TrkB affects survival, differentiation, and invasiveness of human neuroblastoma cells. Cancer Res 1995, 55:1798-1806.
79. Downing K.H., Nogales E. Tubulin structure: Insights into microtubule properties and functions. Curr Opin Struct Biol 1998, 8:785-791.
80. Galmarini C.M. ABT-751 (Abbott). Curr Opin Investig Drugs 2005, 6:623-630.
81. Morton C.L., Favours E.G., Mercer K.S., et al. Evaluation of ABT-751 against childhood cancer models in vivo. Invest New Drugs 2007, 25:285-295.
82. Fox E., Maris J.M., Widemann B.C., et al. A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors. Clin Cancer Res 2008, 14:1111-1115.
83. Buckley P.G., Das S., Bryan K., et al. Genome-wide DNA methylation analysis of neuroblastic tumors reveals clinically relevant epigenetic events and large-scale epigenomic alterations localized to telomeric regions. Int J Cancer 2011, 128:2296-2305.
84. Teitz T., Wei T., Valentine M.B., et al. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 2000, 6:529-535.
85. George R.E., Lahti J.M., Adamson P.C., et al. Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: A children's Oncology Group study. Pediatr Blood Cancer 2010, 55:629-638.
86. Mueller S., Yang X., Sottero T.L., et al. Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: Efficacy and underlying mechanisms. Cancer Lett 2011, 306:223-229.
87. Ruvkun G. Molecular biologyGlimpses of a tiny RNA world. Science 2001, 294:797-799.
88. Lewis B.P., Burge C.B., Bartel D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120:15-20.
89. Wei J.S., Johansson P., Chen Q.R., et al. microRNA profiling identifies cancer-specific and prognostic signatures in pediatric malignancies. Clin Cancer Res 2009, 15:5560-5568.
90. Stallings R.L., Foley N.H., Bryan K., et al. Therapeutic targeting of miRNAs in neuroblastoma. Exp Op Ther Targets 2010, 14:951-962.
91. Oberthuer A., Berthold F., Warnat P., et al. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol 2006, 24:5070-5078.
92. Janoueix-Lerosey I., Schleiermacher G., Michels E., et al. Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol 2009, 27:1026-1033.
93. Vandesompele J., Van Roy N., Van Gele M., et al. Genetic heterogeneity of neuroblastoma studied by comparative genomic hybridization. Genes Chromosomes Cancer 1998, 23:141-152.
94. Islam A., Kageyama H., Takada N., et al. High expression of survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 2000, 19:617-623.
95. Saito-Ohara F., Imoto I., Inoue J., et al. PPM1D is a potential target for 17q gain in neuroblastoma. Cancer Res 2003, 63:1876-1883.
96. Bown N., Cotterill S., Lastowska M., et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med 1999, 340:1954-1961.
97. Diskin S.J., Hou C., Glessner J.T., et al. Copy number variation at 1q21.1 associated with neuroblastoma. Nature 2009, 459:987-991.
98. Maris J.M., Mosse Y.P., Bradfield J.P., et al. Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. N Engl J Med 2008, 358:2585-2593.
99. Capasso M., Devoto M., Hou C., et al. Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. Nat Genet 2009, 41:718-723.
100. Wang K., Diskin S.J., Zhang H., et al. Integrative genomics identifies LMO1 as a neuroblastoma oncogene. Nature 2011, 469:216-220.
101. Mosse Y.P., Laudenslager M., Khazi D., et al. Germline PHOX2B mutation in hereditary neuroblastoma. Am J Hum Genet 2004, 75:727-730.
102. Bradshaw D.M., Arceci R.J. Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. J Clin Oncol 1998, 16:3674-3690.
103. Norris M.D., Bordow S.B., Marshall G.M., et al. Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. N Engl J Med 1996, 334:231-238.
104. Henderson M.J., Haber M., Porro A., et al. ABCC multidrug Transporters in Childhood Neuroblastoma: Clinical and Biological Effects Independent of cytotoxic Drug Efflux. J Natl Cancer Inst 2011, 103:1236-1251.